Allergen-specific immunotherapy (allergen-SIT) is a highly effective treatment for children with allergic asthma (AA), an immune-mediated chronic disease leading to bronchial muscle hypertrophy and airway obstruction in response to specific allergens. T helper cells and secreted cytokines play important roles in the pathogenesis of asthma, and epigenetic modulation controls genes important for T cell development and cytokine expression. This study evaluated T helper cell-secreted cytokines and DNA methylation patterns in children treated with Dermatophagoides pteronyssinus (Der p) allergen-SIT. Our results showed that after Der p challenge, peripheral blood mononuclear cells (PBMCs) from the SIT group, compared with the non-SIT AA group, produced lower levels of IL-4, IL-5 and IL-2. The SIT group, compared with the AA group, exhibited decreased sensitivity to the Der p allergen, concurrent with IL-4 down-modulation due to increased promoter DNA methylation, as estimated in PBMCs. Our results showed that SIT decreased IL-4 and IL-5, and inhibited T cell proliferation, by inhibiting IL-2 production after the specific allergen challenge. These results suggest that decreased IL-2 production and increased IL-4 cytokine promoter methylation is a potential mechanism of Der p-specific allergen desensitization immunotherapy.
INTRODUCTION
Exposure to indoor allergens, such as house dust mites and mold, is strongly associated with asthma. Asthma is an immune-mediated chronic disease, traditionally characterized as a T helper 2 (Th2) immune response, although other T helper populations are also involved. 1 Allergen-specific immunotherapy is a highly effective treatment in which an allergic patient is incrementally exposed to increasing quantities of a specific antigen to 'desensitize' immune responses to the distinct offending antigen. 2 Specific immunotherapy (SIT) is well recognized as an effective treatment for allergic asthma triggered by house dust mites. 3, 4 Several studies, however, have suggested various mechanisms to explain a diminished immunosensitivity via SIT. These postulates include the allergen-SIT diminishment of mast cell and basophil activity, 5, 6 induction of the generation of allergen-specific regulatory T (Treg) cells 5, 7 and regulatory B cells, 8 suppression of allergen-specific Th1 and Th2 cell growth, 8, 9 an increase in allergen-specific IgE blockage by IgG4 upregulation, 10, 11 or a decrease in the allergen-specific IgE/IgG4 ratio. 5, 7, 8 Thus, inhibition of T cell proliferative and cytokine responses to allergen, suggesting anergy, is an alternatively proposed SIT mechanism. 12 However, the details of the immunologic mechanism underlying the effectiveness of allergen-SIT treatments have yet to be fully established.
The differentiation and activation of Th2 cells is a hallmark of allergic asthma, and DNA methylation plays an important role in the differentiation and regulation of T cells. 13 In resting CD4 + T cells, the intergenic region between the IL4 and IFNG genes is methylated. Methylation of the intergenic region between IL-4 and IL-13 suppresses the activation of Th2 cells. 14 In Th2 cells, the IFNG gene is also increasingly methylated. 15 Moreover, a study using an experimental asthmatic animal model found that CD4 + T cells exhibit significantly increased DNA methylation of the IFNG promoter after allergen sensitization. 16 Allergic sensitization also induces demethylation of the IL4 promoter in allergen-specific T cells, 17 and DNA methylation of the IL4 and IFNG promoters has been reported to differ between patients with and without asthma. 18 Previous studies of allergen sublingual and oral immunotherapies have demonstrated that these treatments result in FOXP3 hypomethylation. 5, 7 In this study, we analyzed changes in the DNA methylation of cytokine genes in T helper cells in allergic asthmatic treated with allergen-SIT with the Dermatophagoides pteronyssinus allergen (Der p) over a 3-year period. In addition, various immune parameters, including allergen-specific IgE and IgG4 levels, characterization by a basophil activation test, peripheral blood mononuclear cells (PBMC)-secreted cytokines and cell proliferation, were obtained from PBMCs after Der p stimulation.
MATERIALS AND METHODS
This study was approved by the Ethics Committee of Chia-Yi Christian Hospital in Taiwan (Institutional Review Board No. 103071). Each child and his/her parent or legal guardian provided signed informed consent, in accordance with the Declaration of Helsinki.
Study participants
A total of 37 children aged 6-18 years were enrolled through the Department of Pediatrics at Chia-Yi Christian Hospital. The study assessed 13 allergic asthmatic children who received Der p SIT (SIT), 12 non-SIT allergic asthmatic (AA) controls, and 12 healthy controls (HC). The children in the SIT group that received Der p SIT therapy, according to the protocol recommended by the manufacturer (Table 1) , were consecutively followed up in our outpatient clinic for 3 years. Further details on the methods are provided in Supplementary Information Section.
PBMC isolation and cell culture PBMCs were isolated from heparinized whole blood obtained from the SIT, AA control and HC groups by centrifugation over a Ficoll-Hypaque gradient (GE Healthcare Life Sciences, Uppsala, Sweden). PBMCs were cultured in complete medium: RPMI-1640T cell medium supplemented with 10 mM HEPES, 4 mmol/l L-glutamine, 100 units/ml penicillin/streptomycin, 50 μM 2-mercaptoethanol (2-ME) and 10% heat-inactivated FBS. For antigen challenge, additional Der p was added to the culture medium at a concentration of 100 AU/ml for the in vitro cell culture stimulation. 4 Blood IgE and IgG levels and flow cytometry analysis To determine whether the patients were suited for Der p-specific SIT, the presence of serum Der p-specific IgE antibodies before the onset of SIT, was verified in the SIT group patients. A multiple-antigen simultaneous test chemiluminescent assay (MAST, Hitachi Chemical Diagnostics, Mountain View, CA, USA), a semi-quantitative measurement, was used for detection of total IgE levels in the SIT group (Table 2 , before SIT) before treatment. Total and allergen-specific blood IgE and IgG levels were measured using standard ImmunoCAP assays (Phadia, Uppsala, Sweden) on serum samples from all the subjects (HC, AA and after-SIT groups). For intracellular cytokine staining (ICS) and transcription factor staining, PBMCs were restimulated using a Leukocyte Activation Cocktail with BD GolgiPlug (BD Biosciences, San Jose, CA, USA), containing phorbol myristate acetate, ionomycin and Brefeldin A, for 4-6 h. The cells were then washed with PBS and labeled at 4°C for 30 min in the dark with an anti-CD4 antibody that was directly conjugated to a fluorescence dye. The cells were then fixed with 2% formaldehyde for 10 min at 4°C and subsequently washed and permeabilized in BD Perm/Wash Buffer. An anti-Foxp3 (eBioscience, San Diego, CA, USA) antibody was then used for ICS at 4°C for 30 min in the dark. After the cells were stained, they were washed twice with BD Perm/Wash Buffer and then analyzed through flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA) to count cells expressing specific cytokines.
Basophil activation assay
Freshly isolated PBMCs were cultured in complete medium and stimulated with Der p (100 AU/ml) at 37°C for 30 min to activate the basophils. After culturing, the cells were stained with PE-conjugated CD203 antibodies (BioLegend, San Diego, CA, USA) to analyze CD203 expression in a gated granulocyte population.
Cytokine expression
Cells were stimulated with Der p for 72 h or were left unstimulated, and the culture supernatants were then collected and assayed for IL-2, IL-4, IL-10, IFN-γ and IL-17 expression using a Cytometric Bead Array (CBA, BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions. The culture supernatants were also assayed for IL-5 (Peprotech, Rocky Hill, NJ, USA) and IL-13 (Signosis, Inc., Sunnyvale, CA, 
DNA isolation and pyrosequencing
Genomic DNA was isolated from unstimulated and Der p-stimulated PBMCs using an AllPrep mini DNA kit (Qiagen, Hilden, Germany). Isolated DNA was then bisulfite-converted using an EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA, USA), according to the manufacturer's instructions. For pyrosequencing, bisulfite-converted DNA was used to amplify the promoter regions of IL2, IL4, IL13, RUNX3, CCL17, IFNG and FOXP3, using PCR and sequencing with the primers listed in Supplementary Table S1 . Pyrosequencing was performed on a PyroMark Q24 sequencer, by using the reagents and protocols supplied by the manufacturer (Qiagen, Hilden, Germany).
Statistical analysis
Statistical comparisons were performed using either paired t-tests for paired data (within-subjects by group) or unpaired t-tests for unpaired data (between-subject groups). If the variables did not distribute normally, statistical comparisons were performed using a Wilcoxon matched pair test for paired data or a Mann-Whitney test for unpaired data. Analysis of the study participants' characteristics are shown as the means ± s.d. GraphPad Prism Software version 5 (GraphPad Software Inc., La Jolla, CA, USA) was used for all statistical analysis. A P value of o0.05 was considered statistically significant.
RESULTS

Participants
The characteristics of the study participants are summarized in Table 2 . In the SIT group, before treatment with Der p, six children were classified as having mild persistent asthma, and seven children were classified as having moderate persistent asthma. Moreover, these 13 children exhibited mild respiratory symptoms at the end of the third year of Der p-specific immunotherapy. All SIT patients were therefore classified as having mild intermittent asthma after treatment with Der p SIT. In the AA group, five children were classified as having mild persistent asthma, and seven children were classified as having moderate persistent asthma. There were no significant differences in Asthma Control Test (ACT) scores between the groups before blood collection. Thus, the SIT and AA groups did not differ significantly in terms of age, sex, baseline clinical severity or asthma control level.
Decreased IgE/IgG4 ratio and decreased levels of CD203c in basophils after treatment with Der p SIT Previous reports have indicated that successful treatment with allergen-SIT induces antigen-specific immune tolerance by decreasing the IgE/IgG4 ratio 19 and decreasing basophil activity. 20 To assess whether Der p-specific immunotherapy induced antigen-specific immune tolerance in our three enrolled groups, peripheral blood samples were collected and analyzed to determine immunoglobulin levels and quantify basophil activation. The results of those assays showed that Der p-specific IgE levels were higher in both the SIT and AA groups compared with the HC group ( Figure 1a , SIT vs HC and AA vs HC, Po0.0001). In contrast, the levels of Der p-specific IgG4, which have been shown to block Der p-specific IgE binding to its high affinity FcεRI receptor, 10, 21 were higher in the SIT group, as compared with the serum IgG4 levels in the AA and HC groups (Figure 1b , SIT vs HC, Po0.0001; SIT vs AA, Po0.0001). Similarly, the Der p-specific IgE/IgG4 ratio was decreased in SIT children compared with the ratio observed in AA children ( Figure 1c , SIT vs AA, Po0.0001).
Previous studies have indicated that the altered basophilic cell surface expression of CD203c indicates an allergen-specific immune response. 22 Consequently, we assessed CD203c expression in gated granulocytes from PBMCs of the three enrolled groups after ex vivo stimulation with Der p antigen, and the representative flow figures of SIT and AA are shown in DNA methylation of cytokine genes, particularly IL4, was increased after SIT Epigenetic modification is one of the mechanisms that controls T cell differentiation, and DNA demethylation increases gene expression. 23 To investigate whether the dust mite allergen-SIT changed the DNA methylation of T helper cell cytokine genes, bisulfite-DNA pyrosequencing was performed to assess methylation levels in the Th1-related genes IFNG and RUNX3, the Th2-related genes IL4, IL13 and CCL17, and the T cell activation-related gene IL2 in PBMCs Supplementary Table S2 . were analyzed using a Mann-Whitney test, while (a), (e) and (f) were analyzed using unpaired t-tests. AA, allergic asthma; HC, healthy controls; SIT, specific immunotherapy.
Our results showed that overall DNA methylation levels increased after SIT. Specifically, the methylation levels in the IL4 promoter region, obtained from SIT children's PBMCs, were significantly higher than those from AA children (Figure 2a , AA vs SIT, P = 0.008), and the methylation levels of IL4 after SIT treatment was similar to those from HC children. However, the methylation levels of IL4 of AA patients were significantly lower than IL4 methylation in HCs (Figure 2a , HC vs AA, P = 0.014). Moreover, the methylation levels of IL13, IFNG and IL2 were insignificantly higher in SIT compared with the PBMCs of the AA children. However, the SIT patients' methylation of these genes was significantly higher than those of the HC children (Figures 2b-d, Po0.05) .
Similarly, CCL17 and RUNX3 methylation levels were not significantly different in PBMCs obtained from children in the three study groups (Supplementary Figures S1a and b) . These results indicated a predominant role of increased IL4 promoter methylation after Der p-specific immunotherapy.
Der p-specific IL-2, IL-4 and IL-5 cytokine levels were significantly decreased by SIT In the above data, the DNA methylation of the IL4 promoter region was increased after SIT. To evaluate the expression of cytokines after Der p-specific immune therapy, the supernatants of Der p-stimulated PBMCs were collected and analyzed through a Cytometric Bead Array (CBA) and ELISA. The production of IL-4 by PBMCs stimulated by Der p was lower in SIT and HC children compared with AA children (Figure 3a , P = 0.04). Similarly, the production of IL-5 by PBMCs stimulated by Der p was lower in SIT compared with AA children (Figure 3b , P = 0.02) and insignificantly lower in the HC group compared with the AA group (Figure 3b , P = 0.08). IL-13 production did not show significant differences in the AA, SIT and HC children (Figure 3c , HC vs AA, P = 0.08; AA vs SIT, P = 0.3). In addition, IL-2 levels were significantly decreased in SIT children, as compared with those of the AA and HC children (Figure 3d , P = 0.007 for SIT vs AA; P = 0.03 for SIT vs HCs). In contrast to the changes in IL-2 and IL-4 levels, the amount of IL-10 was higher in AA than in HC children ( Figure 3e , HC vs AA, P = 0.007), but was equivalent between AA children and SIT children (Figure 3e , AA vs SIT, P = 0.2). Moreover, the amounts of IFN-γ and IL-17 in PBMCs were not significantly different among the three study groups (Figures 3f and g ). The above data strongly supported a mechanism for anergic SIT downmodulation of the IL-4 and IL-2 cytokines after ex vivo Der p stimulation.
SIT-modulated T cell responses to allergen through anergy other than CD4 + FoxP3 + T cell alteration Previous reports have indicated that allergen-SIT upregulates Treg cells through the hypomethylation of FOXP3. 5, 7 To investigate whether our enrolled SIT patients demonstrated similar mechanisms, we assessed FOXP3 expression and methylation. The percentage of CD4+ T cells expressing FoxP3 after Der p stimulation was not significantly different between the AA and SIT groups (Figures 4a and b) . Analogously, FOXP3 promoter methylation was not significantly different among the three study groups (Figure 4c ). Moreover, IL-2 production was significantly inhibited in SIT PBMCs after Der p stimulation (Figure 3d ), thus indicating that T cell proliferation might be modulated in SIT patients. Therefore, we performed mixed lymphocyte reactions, which showed profoundly suppressed T cell proliferation in SIT but not AA children after Der p stimulation (Figures 4d and e: P = 0.013). These data indicated that treating asthmatic patients with SIT down-modulated IL-2 production and T cell proliferation but did not change the Treg populations or FOXP3 methylation in our enrolled patients.
DISCUSSION
In this study, we found that specific allergen SIT decreased Der p-specific IL-4, IL-5 and IL-2 cytokine expression (Figures 3a, b and d) in asthmatic children, whereas IL4 promoter methylation was specifically increased after Der p stimulation. •, HC: ▲, *Po0.05 and **Po0.01. Statistical comparisons of (b-f) were analyzed using Mann-Whitney tests, and (a) and (g) were analyzed using unpaired t-tests.
Consequently, the inhibited synthesis of these cytokines and T cell proliferation after ex vivo Der p stimulation indicated a SIT-induced antigen-specific T cell tolerance.
Previous studies have indicated that asthmatic patients exhibit elevated levels of IL-2 in bronchoalveolar lavages and exhaled breath condensates. 24, 25 The levels of measurable IL-2 ) and (e) were analyzed using unpaired t-tests. AA, allergic asthma; HC, healthy controls; SIT, specific immunotherapy. also inversely correlated with forced expiratory volume in one second (FEV1) ACT scores, but were positively associated with eosinophilic infiltration in asthmatic airways. Another clinical study has shown that bee venom T cell peptide treatment induces PLA2-specific T cell anergy and decreased IL-2, IL-4, IL-5 and IL-13 production. 26 Similarly, other work has demonstrated that IL-2 and IL-15 inhibit antigen-specific proliferation of Th1 cells and their synthesis of other cytokines. 27 IL-2 induces naive CD4 + T cells to differentiate into Th2 cells, 28 and neutralizing IL-2 in vivo abolishes the production of IL-4. 29 Our data showed that SIT decreased the Der p-specific expression of the IL-2, IL-4 and IL-5 cytokines (Figures 3a, b and d) . Furthermore, methylation of the IL4 gene was higher in PBMCs obtained from SIT children compared with AA children, thus suggesting that IL4 DNA methylation may increase during Der p SIT desensitization and attenuate the production of IL-4. In combination with the findings described above, our data suggested that the decreased IL-2 levels observed in SIT children might decrease Th2 cell activation and that Th2 cell synthesis of the cytokines IL-4 and IL-5 after Der p stimulation may decrease asthma severity by inducing anergy in Der p-specific naive CD4 + T and Th2 cells.
Allergen-SIT would be effective in decreasing airway eosinophilia and hyper-responsiveness if the SIT induces a decrease in the production of IL-4 and IL-5. In a murine model, the subsequent inhalation challenge with an allergen has revealed an almost complete inhibition of airway eosinophilia and hyper-responsiveness, effects positively correlating with the decreased production of IL-4. 30 Stimulation with Der p decreases IL4 gene DNA methylation in CD4 + cells obtained from AA patients. 18 Furthermore, Cote-Sierra et al. 29 have demonstrated in an in vivo model that anti-IL-2 treatment inhibits priming prior to the production of IL-4; moreover, IL-2 activates STAT5, and this activation is maintained by IL-2, even in IL-4 producing cells. 29 Another previous study has also demonstrated that IL-2 activates STAT5, which in turn binds and induces chromatin remodeling at intron 2 of IL4, thereby promoting Th2 cell differentiation. 31 Specifically, STAT5 binds DNase I hypersensitive sites HSII and HSIII sites of the IL4 gene, 31 and DNA demethylation occurs only around the Th2-specific HS during Th2 differentiation. 32 In our study, IL-2 production was lower in SIT than in AA children ( Figure 3d) ; thus, Der p SIT most probably inhibits the production of IL-4 and induces the hypermethylation of the IL4 gene promoter by decreasing IL-2 signaling.
A previous study in an asthma mouse model has indicated that exposure to diesel exhaust particles augments the production of IgE by inducing the hypermethylation of IFNG and hypomethylation of IL4. 33 Our study has revealed a similar effect in which treatment with Der p SIT increases DNA methylation of the IL4 promoter (Figure 2a) . However, we did not observe a decrease in methylation of the IFNG promoter (Figure 2c ). Numerous studies have indicated that many conserved noncoding sequences (CNSs) before and after promoter regions have various transcription factor binding sites that control the expression of IFN-γ. IFN-γ protein expression is tightly controlled by various transcriptional factors, cytokines, DNA methylation and histone modification, among other modulators. [34] [35] [36] [37] Moreover, two previous studies have shown that IFN-γ, secreted by allergen-specific PBMCs, does not change significantly. 38, 39 Similarly, we observed that the amount of IFN-γ in PBMCs was not significantly different among the three treatment groups in our study (Figure 3f) . Therefore, the decreased production of the IL-2, IL-4 and IL-5 cytokines after specific allergen stimulation may be more relevant to SIT in our study.
In a previous study, it has been found that defective IL-2 production causes intra-islet Treg cell dysfunction, thus resulting in the breakdown of self-tolerance, whereas administering low doses of IL-2 increases Treg cell survival and decreases the incidence of diabetes without activating effector CD8+ T cells in a non-obese diabetic mouse model of type 1 diabetes. 40, 41 Similarly, pretreatment of mice with IL-2 expands the Treg populations and ameliorates experimental allergic encephalitis, myasthenia gravis and graft rejection; 42 thus, these approaches might prove efficacious in treating autoimmune disorders. In addition, low-dose IL-2 increases Tregs, without activating effector T cells, owing to this cytokine's importance for regulatory T cell survival and expansion. Furthermore, peptide studies have demonstrated that antigen increases the numbers of antigen-specific Tregs, but not nonspecific Tregs in allergy patients. 5 Antigen-induced Tregs were present in relatively small numbers compared with nonspecific Tregs. In a previous study, the percentage of CD4 + CD25 + FOXP3 + cells in the peripheral blood have been found not to be significantly higher in the SIT group than in the placebo group. 43 The amounts of IL-2 produced by the PBMCs from SIT children were lower than those from AA and HC children in our study. Moreover, the percentages of CD4 + T cells expressing Foxp3 (Figures 4a  and b ) and exhibiting methylation of the Foxp3 CNS2 region (Figure 4c) were not significantly altered in SIT PBMCs. This lack of methylation change was probably due to decreased IL-2 inhibiting effector T cell proliferation and function as induced by the allergen through anergy mechanisms other than increased Treg cells.
Previous studies have shown that allergen-specific immunotherapy increase IL-2, 44, 45 contradicting to our data. We postulate two reasons for this discordance: (1) the method used to detect the IL-2 cytokine differed between our studies and others, because those groups detected IL-2 from patient's serum during the therapeutic intervals, whereas we detected it from the supernatant of ex vivo Der p-stimulated PBMCs; and (2) it is likely that the therapeutic mechanisms were different, because increased IL-2 may induce regulatory T cells to suppress inflammatory asthmatic responses. However, our data suggested that decreased IL-2 production by PBMCs after Der p stimulation might decrease the Th2 cell populations without inhibiting Treg cell survival, because the amount of IL-2 needed for Treg activation is less than that for the effector cells. 41 IL-10 has anti-inflammatory properties, and its production can be induced in regulatory T and regulatory B cells.
Treatment with SIT has been reported to induce both the up 46 and downregulation 38 of IL-10. However, in addition to the autocrine production of IL-10 by macrophages and dendritic cells, IL-10 is also produced by Th1, Th2 and Th17 cells and is involved in an important negative feedback loop that contributes to the self-regulation of CD4 + T cells. 47 In support of that hypothesis, we found that higher levels of IL-10 were produced in AA than in HC children (Figure 3e ). It is likely that AA children who displayed a Th2 cell-mediated inflammatory response induced IL-10 expression as a self-regulatory function of Th2 cells.
In addition to the abovementioned cytokines, the CCL17 chemokine attracts Th2 cells and induces airway inflammation in asthma. 48 To that end, Runx3 cooperates with T-box transcription factors in repressing IL4 by binding to an IL4 silencer, thus resulting in the upregulation of IFN-γ in Th1 cells. 49 Runx3 is also a molecular link in TGF-β-induced Foxp3 expression during Treg cell differentiation and function. 50 Differential methylation of RUNX3 has previously been associated with childhood asthma in the inner city. 51 However, in our SIT study, the methylation level of these genes was not significantly different compared with that in non-SIT allergic asthmatic children.
Previous reports have indicated that successful allergen-SIT induces allergen-specific immune tolerance by decreasing the IgE/IgG4 ratio 52 and decreasing basophil activity. 20 Moreover, increasing serum IgG4 is compatible with the clinical efficacy of SIT. 53, 54 The expression of CD203c on the surface of basophils stimulated ex vivo with an allergen indicated an allergenspecific immune response. 22 Our observed decrease in the specific Der p IgE/IgG4 ratio (Figure 1c ) and the expression of CD203c (Figure 1f ) on basophils after stimulation with Der p after SIT indicated that Der p specific immunotherapy was effective in blocking Der p specific allergic asthma in the children in our study.
There were no significant differences in allergen-specific IgE between the SIT and AA groups, thus indicating that allergenspecific IgE responses were unchanged by epicutaneous allergenspecific immunotherapy (EPIT). 55 However, allergen-specific IgE tended to decrease more in the SIT group than in the AA group (Figure 1a , SIT vs AA, P = 0.06). Analysis of a greater number of samples might have further increased the significance of the results. Even so, although our sample size was small, we still observed some significant differences in these collected samples. If the sample size were increased, the differences in the treatment groups might be more representative.
In conclusion, our findings indicated that SIT induced Der p-specific tolerance by decreasing the cytokines IL-2, IL-4 and IL-5 while increasing IL4 gene methylation. Der p SIT decreased sensitivity to the Der p allergen and may prevent the development of new allergic sensitization by increasing methylation and downregulating IL4. Moreover, decreasing IL-2 production and T cell proliferation after specific allergen exposure may have clinical implications for allergic therapies that induce anergy in allergen-specific T helper cells. Future larger studies should aim at determining whether some of our observed changes might be used as indicators of successful SIT therapies, in addition to establishing a mechanism(s) for the well-known efficacy of SIT.
